Viewing nowCombinationNewstatin TS Tablet 80/10/20 Milligrams
Telmisartan 80mg · Amlodipine Besylate 13.87mg +1 more
Tablet · Prescription medication · Combination
Samjin Pharmaceutical Co., Ltd.

MFDS item code 201802235 · Approved 2018.05.30 · Insurance code 647804690
Treatment of dyslipidemia and hypertension, inhibition of atherosclerosis progression, and prevention of cardiovascular disease
This medication is used for patients with essential hypertension where blood pressure is not adequately controlled with a combination of Telmisartan and Amlodipine, while Rosuvastatin must be coadministered. Rosuvastatin helps treat lipid disorders in patients with primary and familial hypercholesterolemia, or mixed dyslipidemia who cannot control their lipids through diet and exercise. Additionally, Rosuvastatin is effective in slowing the progression of atherosclerosis and reducing the risk of cardiovascular diseases. Particularly in middle-aged patients with high-sensitivity C-reactive protein levels and additional cardiovascular risk factors, it contributes to risk reduction related to stroke, myocardial infarction, and arterial revascularization. Therefore, this medication is used to effectively manage cardiovascular health by assisting in both blood pressure control and lipid improvement.
Take 1 tablet once daily with water, with or without food. It is recommended to take it at the same time each day, if possible (e.g., in the morning). This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan/amlodipine combination and rosuvastatin. For patients taking a telmisartan/amlodipine combination and rosuvastatin as separate products, treatment may be switched to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. ○ Telmisartan/amlodipine combination Before administering the telmisartan/amlodipine combination, it is recommended that the dose be adjusted using the individual components (amlodipine or telmisartan). However, if blood pressure is not controlled with the individual components, switching directly to the telmisartan/amlodipine combination may be considered as follows. - 40/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or telmisartan 40 mg. - 80/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or this medicine 40/5 mg. - 40/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg. - 80/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg or this medicine 40/10 mg. ◦ Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment. In patients with severe renal impairment, however, it is recommended to start treatment at a low dose and increase the dose gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. ◦ Patients with hepatic impairment: The daily dose of telmisartan should not exceed 40 mg in patients with mild or moderate hepatic impairment. ◦ Older adults: In patients aged 75 years or older, amlodipine clearance is reduced; therefore, treatment should be started at a low dose and the dose increased gradually. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which is sufficient to control the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer, according to LDL cholesterol levels, treatment goals, and the patient's response; the dose may be increased to a maximum of 20 mg daily. 2. Older adults: No dose adjustment is required. 3. Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering rosuvastatin 20 mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to rosuvastatin is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of rosuvastatin is contraindicated in some of these patients. In a drug interaction study of the active ingredients of this medicine, telmisartan/amlodipine 80/10 mg and rosuvastatin 20 mg, rosuvastatin Cmax increased by approximately 2.1-fold and AUC by approximately 1.2-fold in the presence of telmisartan/amlodipine. Therefore, when administering this medicine, assess the potential risk associated with the increase in rosuvastatin Cmax and monitor patients closely.
This medication may cause serious harm to the fetus and newborns in pregnant women, so it must be discontinued immediately if pregnancy is confirmed. Patients with allergies to this drug's active ingredients or similar drugs, hereditary angioedema patients, those with severe liver impairment or bile obstruction, and severe renal impairment patients should not take this drug. Additionally, patients with diabetes or moderate to severe renal dysfunction, those with certain muscle diseases or a history of muscle toxicity should not use this medication. Elderly patients, those with hypotension, slightly impaired liver function, and patients with hyperkalemia should take this medication with more caution and are advised to undergo regular liver function and muscle-related examinations. This medication can cause muscle pain, muscle weakness, and rarely severe muscle damage and renal issues, so patients should see a doctor immediately if symptoms such as muscle pain or cramps appear. This medication can interact with other drugs, so if the patient is taking other medications, they must inform their doctor or pharmacist. Pregnant and nursing women should not take this drug and should use appropriate methods of contraception if necessary. It is not recommended for children under 18 years old as safety and efficacy have not been adequately established. In the event of an overdose, symptoms such as hypotension, dizziness, and worsening renal function may occur, so medical attention should be sought immediately. This medication should be kept out of reach of children and care should be taken not to transfer it to another container.
Peripheral edema, dyspepsia, frequent bowel movements, diabetes mellitus, dizziness, dry vesicular sounds, urticaria, unstable angina, onychomycosis, lumbar spinal stenosis, ear discharge, vertigo, chronic gastritis, various gastrointestinal disorders, hiatal hernia, dysuria, rhinitis, discomfort in the oropharynx, pulmonary disease, unspecified gastrointestinal disease, benign gastrointestinal neoplasm, hemorrhoids, musculoskeletal pain, osteoporosis, sensory impairment, movement disorders, atherosclerosis, frequent urination, tinnitus, hearing loss, bad breath, fatty liver, upper respiratory tract infection, low back pain, sinusitis, diarrhea, pharyngitis, influenza-like symptoms, myalgia, urinary tract infection, abdominal pain, headache, dizziness, pain, fatigue, cough, hypertension, chest pain, nausea, erectile dysfunction, erectile dysfunction, increased sweating, erythema, chest pain, atrial fibrillation, congestive heart failure, myocardial infarction, elevated blood pressure, worsening hypertension, hypotension, hyperkalemia, hypoglycemia, syncope, muscle cramps, bradycardia, eosinophilia, thrombocytopenia, increased uric acid, abnormal liver function, liver disease, acute renal failure, anemia, elevated CPK, anaphylactic reaction, tendon pain, rhabdomyolysis, vascular edema, headache, edema, dizziness, flushing, palpitations, fatigue, nausea, abdominal pain, drowsiness, arrhythmia, bradycardia, chest pain, peripheral ischemia, syncope, orthostatic hypotension, vasculitis, peripheral neuropathy, sensory abnormalities, tremors, dizziness, loss of appetite, constipation, dysphagia, diarrhea, flatulence, pancreatitis, vomiting, gingival hyperplasia, allergic reaction, weakness, low back pain, burning sensation, lethargy, pain, stiffness, weight gain, weight loss, arthralgia, arthritis, muscle cramps, myalgia, sexual dysfunction, insomnia, nervousness, depression, abnormal dreams, anxiety, depersonalization, dyspnea, epistaxis, vascular edema, erythema multiforme, pruritus, rash, erythematous rash, papular rash, visual disturbances, conjunctivitis, diplopia, ocular pain, tinnitus, ear pain, frequent urination, voiding dysfunction, enuresis, dry mouth, hyperglycemia, thirst, leukopenia, purpura, thrombocytopenia, polyneuropathy, memory loss, peripheral neuropathy, cough, dyspnea, diarrhea, jaundice, hepatitis, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms syndrome, lupus-like syndrome, muscle tear, joint pain, weakness, sensory abnormalities, chest discomfort, loss of appetite, abdominal distension, abnormal liver function tests, syncope, generalized pain, muscle cramps, gout
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to light and should be stored in a tightly closed container that blocks light. Additionally, it should be kept at room temperature between 1 to 30 degrees Celsius to maintain its effect.
Oval-shaped, bilayer tablet consisting of a white layer and a light blue layer
30 tablets (10 tablets/PTP x 3)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationTelmisartan 80mg · Amlodipine Besylate 13.87mg +1 more
Tablet · Prescription medication · Combination
Samjin Pharmaceutical Co., Ltd.
CombinationTelmisartan 40mg · Amlodipine Besylate 6.935mg +1 more
Tablet · Prescription medication · Combination
Ildong Pharmaceutical Co., Ltd.
Telmisartan 80mg · Amlodipine Besylate 13.87mg +1 more
Tablet · Prescription medication · Combination
Ildong Pharmaceutical Co., Ltd.
CombinationTelmisartan 80mg · Amlodipine Besylate 6.935mg +1 more
Tablet · Prescription medication · Combination
Il Dong Pharmaceutical Co., Ltd.
CombinationTelmisartan 80mg · Amlodipine Besylate 6.935mg +1 more
Tablet · Prescription medication · Combination
Ildong Pharmaceutical Co., Ltd.
Telmisartan 80mg · Amlodipine Besylate 13.87mg +1 more
Tablet · Prescription medication · Combination
Ildong Pharmaceutical Co., Ltd.
CombinationTelmisartan 40mg · Amlodipine Besylate 6.935mg +1 more
Tablet · Prescription medication · Combination
Ildong Pharmaceutical Co., Ltd.
CombinationTelmisartan 40mg · Amlodipine Besylate 6.935mg +1 more
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.